---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-036006"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:38:59.393841+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech receives Nasdaq delisting notice for non-compliance with equity rule

## Summary
- Received delist determination letter on Nov 20, 2025 for failing to meet $2.5M minimum stockholders' equity requirement.
- Nasdaq will delist on Dec 2, 2025 unless Company requests a hearing panel appeal by Nov 28, 2025.
- Moleculin intends to appeal the determination to stay suspension and continue trading under symbol MBRX.

## SEC filing metadata
- accession: 0001437749-25-036006
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925036006/0001437749-25-036006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925036006/mbrx20251121_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-036006
- JSON: https://secwatch.observer/filing/0001437749-25-036006.json
- Plain text: https://secwatch.observer/filing/0001437749-25-036006.txt

## Source-grounded claims
- claim_id: ae7844a1f56dad0ad228877782f4840711cef5c1
  claim: Moleculin Biotech, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: November 20, 2025, the Company received a delist determination letter from the Staff (the “Nasdaq Notice”) advising the Company that the Staff had determined that the Company had not regained compliance with the Listing Rule. Accordingly, the Staff indicated that unless the Company requests a hearing panel (a “Panel”) appeal of the delist determination by November 28, 2025, its securities would be delisted on December 2, 2025. The Company intends to appeal Nasdaq’s determination to a Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series to stay any suspension pendin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774925036006/0001437749-25-036006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.